BMJ 2001;322:1087-1088 ( 5 May )

Papers

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

Editorial by Little

UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. 

Correspondence to: D Pillay, PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Edgbaston, Birmingham B15 2TT d.pillay{at}bham.ac.uk

Objectives: To identify changes since 1994 in the prevalence of resistance to anti-HIV drugs in primary HIV-1 infections in the United Kingdom.
Design: Retrospective and prospective assessment of viruses obtained from people recently infected with HIV.
Setting: Multiple centres (patients enrolled in the UK register of seroconverters) and a single large HIV clinic (active case ascertainment).
Participants: 69 patients infected with HIV between June 1994 and August 2000.
Main outcome measures: Prevalence of key mutations associated with drug resistance in the reverse transcriptase and protease genes of HIV-1, by year of infection.
Results: Between June 1994 and August 2000, 10 (14%) of 69 newly infected patients had one or more key HIV-1 mutations associated with drug resistance. The risk of being infected with drug resistant virus increased over time (adjusted relative risk per year 1.74 (95% confidence interval 0.93 to 3.27), P=0.06). The estimated prevalence of drug resistance in those infected in 2000 was 27% (12% to 48%).
Conclusions: Transmission of drug resistant HIV-1 in the United Kingdom seems to be increasing. New approaches to encourage safer sexual behaviour in all sectors of the population are urgently needed.

What is already known on this topic The emergence of HIV drug resistance in patients receiving antiretroviral therapy is common Transmission of virus variants resistant to anti-HIV drugs has been documented What this paper adds The prevalence of transmitted HIV drug resistance in the United Kingdom is increasing, exceeding 20% in 2000 New approaches to encourage safer sexual behaviour are urgently needed

---

© BMJ 2001
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Risk compensation: the Achilles' heel of innovations in HIV prevention?

Michael M Cassell, Daniel T Halperin, James D Shelton, and David Stanton
BMJ 2006 332: 605-607. [Full Text] [PDF]

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

UK Group on Transmitted HIV Drug Resistance
BMJ 2005 331: 1368. [Abstract] [Full Text] [PDF]

HIV-1 drug resistance in primary infections in the UK

Sarah Fidler, John Frater, John Clarke, and Jonathan Weber
BMJ 2001 323: 632. [Extract] [Full Text]

Fighting both bugs and tobacco companies
BMJ 2001 322: 0. [Full Text] [PDF]

Fighting both bugs and tobacco companies
BMJ 2001 322: 0. [Full Text] [PDF]

Prevalence of HIV drug resistance is increasing
BMJ 2001 322: 0. [Full Text]

Is transmitted drug resistance in HIV on the rise?

Susan J Little
BMJ 2001 322: 1074-1075. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Herrera, C., Cranage, M., McGowan, I., Anton, P., Shattock, R. J. (2009). Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrob. Agents Chemother. 53: 1797-1807 [Abstract] [Full text]  
• Taiwo, B. O., Murphy, R. (2007). Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 188-197 [Abstract]  
• Booth, C. L., Garcia-Diaz, A. M., Youle, M. S., Johnson, M. A., Phillips, A., Geretti, A. M. (2007). Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59: 517-524 [Abstract] [Full text]  
• Chawla, A., Murphy, G., Donnelly, C., Booth, C. L., Johnson, M., Parry, J. V., Phillips, A., Geretti, A. M. (2007). Human Immunodeficiency Virus (HIV) Antibody Avidity Testing To Identify Recent Infection in Newly Diagnosed HIV Type 1 (HIV-1)-Seropositive Persons Infected with Diverse HIV-1 Subtypes. J. Clin. Microbiol. 45: 415-420 [Abstract] [Full text]  
• Cassell, M. M, Halperin, D. T, Shelton, J. D, Stanton, D. (2006). Risk compensation: the Achilles' heel of innovations in HIV prevention?. BMJ 332: 605-607 [Full text]  
• Gu, Z., Allard, B., de Muys, J. M., Lippens, J., Rando, R. F., Nguyen-Ba, N., Ren, C., McKenna, P., Taylor, D. L., Bethell, R. C. (2006). In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection. Antimicrob. Agents Chemother. 50: 625-631 [Abstract] [Full text]  
• Lee, D. J., Robinson, W. E. Jr. (2006). Preliminary Mapping of a Putative Inhibitor-Binding Pocket for Human Immunodeficiency Virus Type 1 Integrase Inhibitors. Antimicrob. Agents Chemother. 50: 134-142 [Abstract] [Full text]  
• UK Group on Transmitted HIV Drug Resistance, (2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331: 1368- [Abstract] [Full text]  
• Lee, D. J., Robinson, W. E. Jr. (2004). Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to L-Chicoric Acid. J. Virol. 78: 5835-5847 [Abstract] [Full text]  
• Dodds, J P, Mercey, D E, Parry, J V, Johnson, A M (2004). Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample of homosexual men. Sex. Transm. Infect. 80: 236-240 [Abstract] [Full text]  
• Richman, D. D. (2004). Benefits and limitations of testing for resistance to HIV drugs. J Antimicrob Chemother 53: 555-557 [Abstract] [Full text]  
• Scott, P., Arnold, E., Evans, B., Pozniak, A., Moyle, G., Shahmenesh, M., White, D., Shirley, J., Cane, P., Pillay, D. (2004). Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 53: 469-473 [Abstract] [Full text]  
• Pires, I. L., Soares, M. A., Speranza, F. A. B., Ishii, S. K., Vieira, M. C. G., Gouvea, M. I. F. S., Guimaraes, M. A. A. M., de Oliveira, F. E., Magnanini, M. M. F., Brindeiro, R. M., Tanuri, A. (2004). Prevalence of Human Immunodeficiency Virus Drug Resistance Mutations and Subtypes in Drug-Naive, Infected Individuals in the Army Health Service of Rio de Janeiro, Brazil. J. Clin. Microbiol. 42: 426-430 [Abstract] [Full text]  
• Reynolds, S. J., Bartlett, J. G., Quinn, T. C., Beyrer, C., Bollinger, R. C. (2003). Antiretroviral Therapy Where Resources Are Limited. NEJM 348: 1806-1809 [Full text]  
• Grant, R. M., Kuritzkes, D. R., Johnson, V. A., Mellors, J. W., Sullivan, J. L., Swanstrom, R., D'Aquila, R. T., Van Gorder, M., Holodniy, M., Lloyd, R. M. Jr., Reid, C., Morgan, G. F., Winslow, D. L. (2003). Accuracy of the TRUGENE HIV-1 Genotyping Kit. J. Clin. Microbiol. 41: 1586-1593 [Abstract] [Full text]  
• Sarmati, L., Nicastri, E., Uccella, I., d'Ettorre, G., Parisi, S. G., Palmisano, L., Galluzzo, C., Concia, E., Vullo, V., Vella, S., Andreoni, M. (2003). Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. J. Clin. Microbiol. 41: 1760-1762 [Abstract] [Full text]  
• Dumans, A. T., Soares, M. A., Pieniazek, D., Kalish, M. L., De Vroey, V., Hertogs, K., Tanuri, A. (2002). Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naive Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro, Brazil. Antimicrob. Agents Chemother. 46: 3075-3079 [Abstract] [Full text]  
• Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., Richman, D. D. (2002). Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. NEJM 347: 385-394 [Abstract] [Full text]  
• Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P., Kahn, J. O. (2002). Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. JAMA 288: 181-188 [Abstract] [Full text]  
• Trachtenberg, J. D., Sande, M. A. (2002). Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge. JAMA 288: 239-241 [Full text]  
• Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full text]  
• Houston, S. (2002). Justice and HIV Care in Africa--Antiretrovirals in Perspective. J Int Assoc Physicians AIDS Care (Chic Ill) 1: 46-50 [Abstract]  
• Bird, S. M, Brown, A. J L. (2001). Criminalisation of HIV transmission: implications for public health in Scotland. BMJ 323: 1174-1177 [Full text]  
• Poulton, M, Curtis, S, McElborough, D, Williams, D I, Fisher, M (2001). Syphilis: mimicking yet another disease!. Sex. Transm. Infect. 77: 325-325 [Full text]  
• Kegg, S., Pittrof, R., Lau, R. (2001). Homosexual men, HIV, and sexual risk in 2001. Sex. Transm. Infect. 77 : 325-326 [Full text]  
• Saloojee, H., Violari, A. (2001). Regular review: HIV infection in children. BMJ 323: 670-674 [Full text]  
• Fidler, S., Frater, J., Clarke, J., Weber, J. (2001). HIV-1 drug resistance in primary infections in the UK. BMJ 323: 632-632 [Full text]  
• Little, S. J (2001). Is transmitted drug resistance in HIV on the rise?. BMJ 322: 1074-1075 [Full text]  

Rapid Responses:

Read all Rapid Responses

Analysis of prevalence of HIV-1 drug resistance in primary infections

Sarah Fidler, et al.
bmj.com, 22 May 2001 [Full text]

Imported HIV infection: the danger of stigmatisation

Adil Isaac, et al.
bmj.com, 7 May 2003 [Full text]

Online poll

Find out more on doc2doc >>